<DOC>
	<DOCNO>NCT01356303</DOCNO>
	<brief_summary>This phase II , open-label clinical study prospectively enrol 40 metastatic patient non small cell lung cancer . The study enroll patient King Abdulaziz Medical City , Riyadh . Sub-sites open patient accrual select center Kingdom .</brief_summary>
	<brief_title>Docetaxel Combined With Cisplatin First Line Patients With Metastatic Non-small Cell Lung Cancer</brief_title>
	<detailed_description>The cisplatin/docetaxel establish standard first line management metastatic non small cell lung cancer United States , Europe Asia . However , safety efficacy regimen study systematically Middle Eastern population . The aim study study efficacy safety regimen patient population</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically cytologically proven nonsmall cell lung carcinoma Stage IV metastatic nonsmall cell lung carcinoma stage III malignant pleural effusion . Patient eligible customization chemotherapy ( available participate institution ) . Having least one measurable lesion Patient life expectancy 12 week great . Age &gt; 18 year . No prior systemic treatment metastatic lung cancer . Adjuvant treatment give 1 year ago acceptable . WHO performance status 02 ( See Appendix III ) Adequate organ function : Hematology : Neutrophils &gt; 2 x 10 9 /L , platelet &gt; 100 x 10 9 /L Hepatic function : Total bilirubin &lt; 1.25 time upper normal limit , ASAT ( SGOT ) &lt; 2 time upper normal limit Renal function : Creatinine &lt; 1.5 mg/dL ; value high upper normal limit le 2 mg/dL , creatinine clearance &gt; 60min/ml . Able comply schedule followup management toxicity Signed inform consent patient legal representative Negative urine pregnancy test ( indicate ) Pregnant lactate woman woman childbearing potential use inadequate contraception . Uncontrolled brain metastatic disease . ( CNS disease stable &gt; 4 week radiotherapy lieu steroid reduction eligible ) . Symptomatic peripheral neuropathy &gt; grade 1 accord NCI Common Toxicity Criteria Version 3 Other serious illness medical condition : Unstable cardiac disease require treatment History significant neurologic psychiatric disorder include psychotic disorder , dementia seizure Active uncontrolled infection Concurrent treatment experimental drug . Participation another clinical trial investigational drug within 30 day prior study screen Concurrent treatment anticancer therapy Contraindication steroid drug administration Past ( 5 year ) concurrent history neoplasm except curatively treat non melanoma skin cancer situ carcinoma cervix</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Lung cancer</keyword>
</DOC>